Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy RICHLAND, WASHINGTON – September 24, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment...
Overall Ten-Year Biochemical Success Rate for Entire Group Was 96.2% Largest and Longest Followed Series of Cesium-131 Treated Patients Reported to Date RICHLAND, WASHINGTON – September 18, 2019 –A recent publication is drawing attention for its positive report on a...
Conference Call is Tuesday, September 24, 2019, at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
RICHLAND, WASHINGTON – September 10, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced today that it will spotlight the growing cancer...
RICHLAND, WASHINGTON – August 13, 2019 – Studies recently reported at scientific meetings and published in medical journals illustrate that Isoray, Inc.’s (NYSE AMERICAN: ISR) Cesium Blu™ is making an important difference in providing treatment options for...
New Brand Identity to Be Unveiled Thursday, June 13 RICHLAND, WASHINGTON – June 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced...
